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Transient neonatal cystinuria.
Background. Cystinuria is an inherited disorder of luminal
reabsorptive transport for cystine and dibasic amino acids in
the renal proximal tubule. Two cystinuria genes have been
identified. Mutations of SLC7A9, which encodes the luminal
transport channel itself, tend to be dominant and mutations
of SLC3A1 (rBAT), which encodes a transporter subunit, are
always recessive. Patients who inherit two recessive mutations
or two dominant mutations have equally severe forms of cystin-
uria. Heterozygotes excrete cystine in the normal (type I), mod-
erate (type III), or high stone-forming (type II) range.
Methods. Infants with cystinuria were identified via the Que-
bec Newborn Urinary Screening Program. In a subgroup of
these infants, cystinuria was severe in the first months of life,
but partially resolved by 2 to 4 years postnatally. We assigned
each patient a final cystinuria phenotype at 3 to 4 years. In ad-
dition, we characterized SLC3A1 gene expression in fetal and
postnatal human kidney.
Results. Most infants with transient neonatal cystinuria are
eventually classified as type III heterozygotes. All infants with
mutant cystinuria genes have exaggerated neonatal cystine ex-
cretion except those who inherit two SLC3A1 mutations (type
I/I cystinuria); these children have persistent severe cystinuria,
implying that wildtype SLC3A1 is required for the maturational
effect. Expression of SLC3A1 mRNA was found to be tenfold
higher in postnatal vs. fetal kidney; SLC3A1 expression is dou-
bled by the proximal tubule transcription factor, PAX8. rBAT
is expressed in the proximal convoluted and straight tubules in
both fetal and adult kidney.
Conclusion. Maturation of SLC3A1 gene expression be-
tween midgestation and 4.5 years postnatal age may account
for transient neonatal cystinuria.
Cystinuria is an inherited disorder of reabsorptive
transport of cystine and the dibasic amino acids (or-
nithine, lysine, and arginine) in the renal proximal tubule
and small intestine. The only known clinical consequence
of cystinuria is recurrent nephrolithiasis. Normally, 99%
of cystine in the glomerular filtrate is reabsorbed by trans-
porters located along the luminal brush border mem-
brane of proximal tubular cells; however, patients who
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inherit two mutant cystinuria genes may excrete cys-
tine in amounts ranging from 50% to 200% of the fil-
tered load. In the collecting duct, where luminal pH falls
and tubular fluid can become hypertonic, cystine con-
centration exceeds its limit of solubility in urine (about
1200 lmol/L) and forms hexagonal crystals which may
coalesce to form large cystine-based stones. Although
cystinuria is not lethal, recurrent stone formation begins
in childhood, with a high likelihood of multiple operative
procedures for stone removal and/or nephrectomy, com-
pared to calcium oxalate stone formers. About 50% of
symptomatic patients report onset of stone formation in
the first decade of life, and another 30% to 40% experi-
ence nephrolithiasis as teenagers [1].
In 1955, Harris et al [2] first proposed that there are
at least two types of cystinuria (fully recessive and in-
completely recessive) distinguished by the level of uri-
nary cystine excretion in heterozygotes. In some families,
cystinuria is fully recessive; carriers are clinically silent
(type I), with urinary cystine excretion levels in the nor-
mal range (<100 (lmol/g creatinine), while probands ex-
crete cystine at markedly high levels in the stone forming
range (>1500 lmol/g creatinine) [3]. This fully recessive
form of cystinuria was shown to be due primarily to inac-
tivating mutations of a gene (SLC3A1) on chromosome
2p21 [4–8]. SLC3A1 encodes a 685 amino acid glyco-
protein (rBAT), which interacts directly with the cystine
transport channel protein, chaperoning it to the luminal
surface of proximal tubular cells [9, 10]. It has been pro-
posed that patients who inherit two mutant rBAT genes
be referred to as A-type cystinurics [11].
In families with dominant cystinuria, heterozygotes
excrete cystine at moderately (type III) elevated levels
(>100 lmol cystine/g creatinine) or even in the stone-
forming (>1200 lmol cystine/g creatinine) range (type
II). Although it was initially thought that there might be
more than one dominant form of cystinuria, both type III
and type II families have usually been shown to bear mu-
tations of the SLC7A9 gene on chromosome 19q12-13.
SLC7A9 encodes the 487 amino acid proximal tubule lu-
minal membrane cystine transport channel, itself [12]. In
keeping with the genotypic classification above, patients
inheriting two SLC7A9 mutations could be considered to
have B-type cystinuria.
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Adults and older children who inherit mutant cystin-
uria genes exhibit definable urinary phenotypes but uri-
nary cystine excretion patterns may be wildly distorted
by the effects of proximal tubular transport maturation
in the newborn period. Scriver et al [13] observed that
some neonates initially appear to have severe cystin-
uria (markedly elevated urinary cystine levels >2000
to 3000 lmol/g creatinine) but subsequently their cys-
tine excretion drops below the stone-forming range
(<1000 lmol/g creatinine) during the first year or two
of life. In this study, we reexamine the phenomenon of
transient neonatal cystinuria by defining the final cystin-
uria phenotype (type I, II, or III) of affected infants and
characterizing the developmental expression of SLC3A1
and SLC7A9 genes in human kidney.
METHODS
Ontogeny of urinary cystine excretion
The Quebec Network of Genetic Medicine maintains a
urinary screening program for several heritable diseases;
infants with elevated excretion of cystine are identified
and referred for further investigation. Fresh urine sam-
ples from newborns referred to the Montreal Children’s
Hospital, their parents, and siblings were obtained. Uri-
nary cystine, ornithine, lysine, and arginine were quanti-
fied by elution chromatography on ion-exchange resin
columns with a Beckman 6300 amino acid analyzer
(Beckman Instruments, Mississauga, Ontario, Canada).
Urinary phenotype was assigned for parents according
to the following classification. Type I heterozygote de-
fines urinary cystine <100 lmol/g creatinine; type III het-
erozygote refers to urinary cystine 100 to 1200 lmol/g
creatinine. Final classification of probands and siblings
was based on the urinary phenotype at 4 years of age.
Serial measurements of cystine excretion were made on
45 children with the following final cystinuria classifica-
tions: 8 type I/I, 18 type I/III, and 1 type III/III cystinuria
proband(s); 2 type I/N and 17 type III/N heterozygotes.
All eight type I/I patients were shown to have inherited
two mutant rBAT mutations [7, 8].
Northern analysis of SLC3A1
Total RNA was prepared from frozen tissues by
the guanidine isothiocyanate/cesium chloride procedure.
Twenty-five micrograms per lane was electrophoresed
through a 1% agarose/formaldehyde gel and transferred
overnight to a Hybond-N membrane (Amersham) in
10 × standard sodium citrate (SSC). The RNA was then
cross-linked with ultraviolet light. SLC3A1 full-length
cDNA probe was radiolabeled using DECA prime II
DNA labeling (Ambion). The Northern blot was prehy-
bridized for 3 hours, then probed overnight at 42◦C in
50% formamide, 2.5 × Denhardt’s solution, 25 mmol/L
KPO4 (pH 7.4), 0.1% sodium dodecyl sulfate (SDS), 10%
(wt/vol) dextran sulfate, 5 × SSPE, and 500 lg/mL herring
sperm DNA (Sigma). The blot was then washed twice in
2 × SSPE, 0.1% SDS at room temperature for 20 min-
utes and exposed to BioMax MR x-ray film (Kodak,
Rochester, NY, USA) overnight at −80◦C. Ethidium
bromide–stained gel of total RNA was used to demon-
strate equivalent loading in both lanes.
rBAT immunostaining
The 111/2-week-old fetal kidney tissue was obtained
with informed consent at the time of therapeutic abor-
tion; normal kidney tissue was obtained from a 41/2-year-
old girl undergoing partial nephrectomy for a well-
encapsulated Wilms’ tumor. Tissues were incubated in
freshly prepared 4% paraformaldehyde in phosphate-
buffered saline (PBS) for 18 hours and stored at 4◦C in
70% EtOH prior to embedding in paraffin. Serial 5 lm
sagittal sections of the kidney tissues were prepared on
Superfrost/Plus slides (Fisher). For immunohistochem-
ical analysis, kidney sections were deparaffinized and
incubated with polyclonal antihuman MANRx (rBAT)
antibody (10 lg/mL) in PBS, supplemented with
20 mmol/L glycine and 1% bovine serum albumin (BSA),
overnight at 4◦C. rBAT antibody was detected with Vec-
tastain ABC Rabbit IgG kit (Vector Laboratories) as de-
scribed by the manufacturer, followed by incubation with
diaminobenzidine (DAB) substrate (Sigma). Sections
were washed in PBS, counterstained with hematoxylin,
dehydrated and mounted with Permount (Fisher). Fetal
and pediatric tissues were stained simultaneously, along
with negative controls (lacking primary antibody); each
analysis was repeated three times.
Cotransfection studies of SLC3A1 and PAX8
Previously constructed vectors. Cytomegalovirus
(CMV)-PAX8 expression vector and SLC3A1-CAT re-
porter construct were used in transient cotransfection as-
says. They were transiently transfected by the calcium
phosphate method and the cells were harvested 72 hours
later with Tris-ethylenediaminetetraacetic acid (EDTA)-
NaCl (TEN), pelleted, and submitted to three freeze-
thaw cycles. Cell lysate supernatants were assayed for
CAT (cpm) and normalized for b-galactosidase activity.
Urinary phenotype of patients heterozygous for PAX8
mutations
We analyzed urine samples from five patients with
proven PAX 8 mutations and congenital thyroid hypopla-
sia. Patient 1 carried a de novo heterozygous R108 stop
mutations while the other four had various missense mu-
tations described elsewhere [16]. Fresh urine samples
were obtained from the aforementioned patients and un-
affected family members by Dr. H. Krude in Germany
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Fig. 1. Urinary cystine excretion of type I/N (two patients) and type
III/N (17 patients) in the first 4 years of life. Each point represents the
mean ± SEM.
and frozen at −20◦C prior to analysis on an automated
amino acid analyzer as described above.
RESULTS
Transient neonatal cystinuria
Neonates identified by the Quebec Neonatal Urine
Screening Program, later classified as type III/N heterozy-
gotes, exhibited markedly elevated urinary excretion of
cystine (mean = 3621 lmol cystine/g creatinine) 1 to
2 months after birth. However, by 4 years of age, these
children had only moderate cystinuria (mean = 318 lmol
cystine/g creatinine) typical of incompletely dominant
heterozygous type III/N adults bearing SLC7A9 muta-
tions. Type I/N heterozygous neonates, culled from fam-
ilies of proven type I/I cystinuria probands with proven
SLC3A1 mutations, had a milder elevation of cystine ex-
cretion in the neonatal period (mean = 875 lmol cystine/g
creatinine); nevertheless, these infants also demonstrated
a significant maturational effect, reaching normal levels
within 1 year (mean = 17, normal ≤100 lmol cystine/g
creatinine) (Fig. 1).
Similarly, type I/III children showed very high levels of
cystine excretion at birth (mean of 5560 lmol cystine/g
creatinine), which dropped to a mean level of 1051 lmol
cystine/g creatinine by early childhood; cystine excretion
in the one type III/III patient also fell from 9000 lmol cys-
tine/g creatinine in the first months of life to 2719 lmol
cystine/g creatinine after 4 years of age. By contrast, type
I/I patients (mean of 4601 lmol cystine/lg creatinine at
birth) showed no significant decline over the first 4 years
of life (mean of 5143 lmol cystine/g creatinine) [14]
(Fig. 2). Since glomerular filtration rate increases dra-
matically in infancy, we also calculated cystine excretion
as a fraction of the filtered load for each homozygote (or
compound heterozygote). Fractional excretion of cystine
diminished with age for type III/III and type I/III pa-
tients but not for type I/I homozygotes (Table 1). These
observations suggest the maturational effect involved in
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Fig. 2. Urinary cystine excretion of type I/I (eight patients) and Type
I/III (18 patients) in the first 4 years of life. Each point represents the
mean ± SEM.
transient neonatal cystinuria requires at least one normal
copy of the SLC3A1 gene.
Expression pattern of rBAT
In view of the observations above we were particularly
interested to characterize the developmental expression
of the SLC3A1 gene product (rBAT) in human kidney.
In a sample of 111/2 week gestation human fetal kidney,
specific rBAT immunoreactivity was noted in both con-
voluted and straight portions of the proximal tubule. This
included the proximal S1 segment since immunostaining
was seen in cortical convoluted tubules directly emerging
from glomeruli (Fig. 3). rBAT expression was also seen in
the proximal pars recta (S3) in medullary sections of fetal
kidney (Fig. 3). A similar pattern of rBAT expression was
seen in postnatal (41/2 years) kidney, with specific staining
of medullary S3 (Fig. 4A) as well as cortical S1 (Fig. 4B)
segments of the proximal tubule. Negative controls (no
primary antibody) lacked staining in these structures.
SLC3A1 mRNA expression
Total RNA was isolated from fetal (18 weeks’ gesta-
tion) and postnatal human kidney (41/2 years old) sam-
ples. Northern analysis (25 lg/lane) showed a significant
(tenfold) increase in SLC3A1 expression between the fe-
tal and pediatric kidney samples after normalization for
b-actin mRNA (Fig. 5).
SLC3A1 promoter is activated by PAX8
During kidney development, the fetal proximal tubule
expresses the transcription factor, PAX8. Since this coin-
cides with the distribution of rBAT expression, we consid-
ered PAX8 as a candidate regulator of SLC3A1. Kozmik,
Czerny, and Busslinger [15] reported a loose recogni-
tion motif, A GCA TCA, found in several of PAX8’s
established downstream targets; this motif appears in the
SLC3A1 promoter from –64 bp to –72 bp. Cotransfection
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Fig. 3. rBAT expression in proximal convoluted tubule (PCT) and
proximal straight tubule (PST) of fetal kidney tissue.
studies using a PAX8 expression vector and the SLC3A1
promoter in a proximal tubular cell line [opossum kidney
(OK) cells] showed a twofold increase in the promoter’s
activity in the presence of the renal transcription factor
(Fig. 6). To determine whether heterozygous PAX8 muta-
tions disturb normal SLC3A1 maturation, causing cystin-
uria, we investigated five patients with proven PAX8
mutations and congenital hypothyroidism [16]. The urine
amino acid profiles of these patients were entirely within
the normal range as were unaffected family members.
DISCUSSION
In 1985, Scriver et al [13] noted that more than half of
the infants referred to the Montreal Children’s Hospital
gradually reduce their cystine excretion below the stone-
forming range and eventually exhibit only modest cystin-
uria. This created a problem for the Quebec Newborn
Urine Screening Program, since cystinuria heterozygotes
who have minimal long-term risk of nephrolithiasis are
Fig. 4. (A) rBAT expression in proximal straight tubule (PST) and (B)
proximal convoluted tubule (PT) of pediatric kidney tissue.
confused with homozygous type I/I or type III/III cystin-
urics who are likely to have recurrent stone formation
beginning in childhood. By confirming the presence of
severe cystinuria (>1200 lmol cystine/g creatinine) at the
age of 12 to 18 months, we now avoid unnecessary refer-
rals, but the basis for transient neonatal cystinuria is not
fully understood.
In this study, we show that most infants who exhibit
transient neonatal cystinuria are eventually classified as
type III heterozygotes after 1 to 2 years, excreting cys-
tine in the range of one of their parents. Presumably this
reflects an interaction between the perinatal maturation
of proximal tubular transport mechanisms and the pres-
ence of a single mutant SLC7A9 allele. Although less
dramatic, the same maturational phenomenon was noted
in children who inherit a single mutant SLC3A1 allele.
However, neonatal cystinuria did not resolve in type I/I
homozygotes, suggesting that at least one normal copy of
the SLC3A1 gene must be present to observe the matura-
tional effect. Thus, transient neonatal cystinuria requires
maturation of SLC3A1 expression, and is independent of
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Fig. 5. (A) Northern blot of total RNA from fetal and pediatric kid-
ney tissue (25 lg/lane) (arrow indicates the 2.4 kb rBAT transcript).
(B) Ethidium bromide–stained agarose gel as a control for equivalent
quantities of fetal and pediatric kidney RNA samples.
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Fig. 6. Transient cotransfection of 0.8 kb rBAT promoter-CAT con-
struct ± mPAX8. Activity of the rBAT promoter is increased twofold.
Bars represent means of three experiments each done in triplicates.
SLC7A9 maturation or maturation of the whole proximal
tubule.
Several lines of evidence suggest that bulk reabsorp-
tive transport of amino acids occurs in the convoluted
S1 and S2 segments of the renal proximal tubule, while
high-affinity mechanisms in the S3 (pars recta) segment
extract the remainder [17]. Early studies by Yan et al
[18], Kanai et al [19], and Furriols et al [20] suggested
that rBAT mRNA is largely restricted to S3 cells of the
straight proximal tubule in rodent kidney. If the same
were true in humans, transient neonatal cystinuria might
be explained by gradual maturation of rBAT expression
in the pars recta, partially compensating for defective
bulk reabsorption in the convoluted tubules of SLC7A9
heterozygotes. However, our studies show diffuse expres-
sion of rBAT protein throughout the cortical convoluted
and medullary straight proximal tubule in both fetal and
postnatal kidney. Thus, rBAT presumably serves trans-
port mechanisms in all segments of the human proximal
tubule.
By Northern analysis, renal expression of SLC3A1
mRNA begins in early fetal life but increases substantially
by 41/2 years of age. The pattern of rBAT expression cor-
relates with the immature cystine transport activity found
in carriers and patients with one functioning SLC3A1 al-
lele, implying that the maturation of rBAT expression
is involved in transient neonatal cystinuria. Although
normal neonatal kidney samples were unavailable for
analysis, it is conceivable that cystinuria gene expres-
sion is incomplete at birth and matures during the time
frame corresponding to the period of transient neonatal
cystinuria.
In fetal kidney, PAX8 is expressed in proximal tubular
cells during terminal differentiation and persists in the
mature proximal tubule after birth [21]. Our transfection
studies demonstrate a twofold activation of SLC3A1 pro-
moter activity by PAX8 which may, therefore, be involved
in the initial expression of the gene in fetal kidney. How-
ever, it seems unlikely that this modest effect of PAX8 is
the only determinant of SLC3A1 expression and our stud-
ies do not allow us to conclude whether PAX8 is involved
in the perinatal increase of SLC3A1 mRNA. Moreover,
we screened five patients with heterozygous PAX8 muta-
tions for cystinuria but found that they had entirely nor-
mal urine amino acid profiles. The PAX8 mutations in
these patients were sufficient to disrupt normal thyroid
development since each patient had congenital hypothy-
roidism [16], yet there was no impact on proximal tubular
function Although PAX8 may influence SLC3A1 expres-
sion, other unknown regulatory factors presumably play
a more important role.
CONCLUSION
Our data favor a model of transient neonatal cystin-
uria in which proximal tubule reabsorption of cystine and
dibasic amino acids is sensitive to SLC7A9 gene dosage.
At birth, immaturity of SLC3A1 (rBAT) expression tran-
siently limits full function of the remaining wild-type
SLC7A9 allele, exaggerating cystinuria in the first year
or two of life.
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